Vicriviroc in HIV(R5/X4)-Treatment Experienced Subjects (Study P05057AM5)(COMPLETED)

Sponsor

Merck Sharp & Dohme LLC (Industry)

Overall Status

Completed

CT.gov ID

NCT00551330

Collaborator

(none)

111

Enrollment

Arms

Duration (Months)

Study Details

Study Description

Brief Summary

Vicriviroc (vye-kri-VYE-rock) is an investigational drug (not yet approved by Government Regulatory Authorities for commercial use) that belongs to a new class of drugs, called CCR5 receptor blockers. This group of drugs blocks one of the ways HIV enters T-cells (the cells that fight infection). Previous smaller studies in HIV treatment-experienced patients, have shown that vicriviroc is safe and effective. The purpose of this study is to investigate in subjects with detectable dual/mixed CCR5/CXCR4-tropic HIV whether vicriviroc when added to other appropriate HIV drugs can decrease the level of HIV (viral load) in the blood and that it is well tolerated.

This is a randomized, double-blind, placebo-controlled, parallel-group, multi-center study of vicriviroc maleate in HIV subjects infected with dual/mixed CCR5/CXCR4-tropic virus and who have documented resistance to at least 2 of the 3 antiretroviral drug classes (NRTI, NNRTI or PI) or at least 6 months experience with at least 2 of the following: one NRTI, one NNRTI, or one PI (excluding low-dose ritonavir) and failure on their current stable regimen. The study will compare the virologic benefit of adding vicriviroc to an optimized background regimen to a control group receiving placebo plus the new optimized background therapy. The optimized background regimen will be chosen by the investigator based on results of drug susceptibility tests performed at Screening, history of prior antiretroviral drug use by the patient, and drug toxicity. Primary efficacy analysis will be conducted when all subjects have completed 48 weeks of treatment. An interim analysis will be performed when all subjects have completed 24 weeks of treatment. Subjects who complete 48 weeks of treatment, or who discontinue early but are deemed eligible upon rescreening, will be offered participation in the open-label segment of the study, and will receive vicriviroc 30 mg once daily, if appropriate, until commercially available or until the sponsor terminates the clinical development of vicriviroc.

Condition or Disease	Intervention/Treatment	Phase
HIV Infections Acquired Immunodeficiency Syndrome	Drug: Vicriviroc Drug: Placebo	Phase 2

Study Design

Study Type:

Interventional

Actual Enrollment :

111 participants

Allocation:

Randomized

Intervention Model:

Parallel Assignment

Masking:

Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

Primary Purpose:

Treatment

Official Title:

Vicriviroc in Combination Treatment With an Optimized ART Regimen in Treatment-Experienced Subjects With R5/X4 HIV Infection (VICTOR-E2; Protocol No. P05057)

Study Start Date :

Sep 1, 2007

Actual Primary Completion Date :

Feb 1, 2010

Actual Study Completion Date :

May 1, 2010

Arms and Interventions

Arm	Intervention/Treatment
Experimental: 1 Vicriviroc 30 mg QD	Drug: Vicriviroc One tablet of vicriviroc 30 mg once daily
Placebo Comparator: 2 Placebo	Drug: Placebo One tablet of placebo once daily

Arm

Intervention/Treatment

Experimental: 1

Vicriviroc 30 mg QD

Drug: Vicriviroc

One tablet of vicriviroc 30 mg once daily

Placebo Comparator: 2

Placebo

Drug: Placebo

One tablet of placebo once daily

Outcome Measures

Primary Outcome Measures

Change from baseline in HIV RNA (log10 copies/mL) [At Week 48]

Secondary Outcome Measures

Change from baseline in CD4 count [At Week 24 and Week 48]

Eligibility Criteria

Criteria

Ages Eligible for Study:

16 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Subjects must be at least 16 years of age (or minimal age that defines an adult as determined by local regulatory authorities or legal requirements), of either sex and of any race, with dual/mixed CCR5/CXCR4 tropic HIV infection.
Subjects must have treatment failure (defined by plasma HIV RNA [ribonucleic acid]

1000 copies/mL) on an existing regimen.

Subjects must be antiretroviral therapy (ART)-experienced and have documented genotypic and/or phenotypic resistance to at least one drug in 2 of the following 3 drug classes: nucleoside reverse transcriptase inhibitor (NRTI), nonnucleoside reverse transcriptase inhibitor (NNRTI), or protease inhibitor (PI)

Antiretroviral class experience for at least 6 months (sequential or cumulative) with at least two of the following:
one NRTI
one NNRTI
one PI (excluding low dose ritonavir).
In the opinion of the investigator, the best treatment regimen for the subject must be an optimized ART regimen consisting of >=3 drugs, the optimized regimen must contain at least 2 active drugs, one of which must be a ritonavir-boosted PI (>=100 mg ritonavir). With the exception of etravirine, NNRTIs may not be a component of the optimized regimen.

Exclusion Criteria:

Any condition likely to increase the risk of seizures.
CD4 count <100 cells/mm^3.
Current or prior history of malignancy.

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

Merck Sharp & Dohme LLC

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

Responsible Party:

Merck Sharp & Dohme LLC

ClinicalTrials.gov Identifier:

NCT00551330

Other Study ID Numbers:

P05057

First Posted:

Oct 30, 2007

Last Update Posted:

Dec 21, 2015

Last Verified:

Dec 1, 2015

Keywords provided by Merck Sharp & Dohme LLC

Treatment Experienced

Additional relevant MeSH terms:

Infections

HIV Infections

Acquired Immunodeficiency Syndrome

Immunologic Deficiency Syndromes

Study Results

No Results Posted as of Dec 21, 2015